Zai Lab (ZLAB) said Wednesday that data from the China subpopulation of a global phase 3 trial showed an improved overall survival after treatment with Tivdak in patients with recurrent or metastatic cervical cancer compared with chemotherapy.
The company said the China results were consistent with those seen in the global population as the drug candidate showed a 45% decrease in the risk of death compared with chemotherapy.
Main secondary endpoints of progression-free survival and objective response rate also "favored treatment with Tivdak compared to chemotherapy," Zai Lab said.
The company said it plans to file a new drug application with China's National Medical Products Administration in Q1.
ZLAB shares were up 2.8% in early trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。